Michael King
Stock Analyst at EF Hutton
(1.04)
# 3,505
Out of 4,820 analysts
117
Total ratings
34.15%
Success rate
-16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $6.56 | +9,808.54% | 4 | Apr 1, 2024 | |
| SONN Sonnet BioTherapeutics Holdings | Assumes: Buy | $1,179 | $1.37 | +85,972.99% | 7 | Aug 23, 2023 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $3.63 | +203.03% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $2.18 | +1,371.26% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $4.68 | +1,363.68% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $7.70 | +2,497.40% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.87 | +858.32% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $602.64 | +43.04% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $37.43 | -35.88% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $2.71 | +6,025.46% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $10.45 | +301.91% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $251.56 | +20.85% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $8.31 | +1,295.91% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.94 | +432.30% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $32.82 | -26.87% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $0.73 | +109,085.21% | 2 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $20.70 | +122.22% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $29.52 | +225.20% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.83 | +4,245.20% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.37 | +3,117.16% | 1 | Dec 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $4.62 | +571.00% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $614.76 | -94.14% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $6.56
Upside: +9,808.54%
Sonnet BioTherapeutics Holdings
Aug 23, 2023
Assumes: Buy
Price Target: $1,179
Current: $1.37
Upside: +85,972.99%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $3.63
Upside: +203.03%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $2.18
Upside: +1,371.26%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $4.68
Upside: +1,363.68%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $7.70
Upside: +2,497.40%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.87
Upside: +858.32%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $602.64
Upside: +43.04%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $37.43
Upside: -35.88%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $2.71
Upside: +6,025.46%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $10.45
Upside: +301.91%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $251.56
Upside: +20.85%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $8.31
Upside: +1,295.91%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $1.94
Upside: +432.30%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $32.82
Upside: -26.87%
Mar 11, 2022
Maintains: Buy
Price Target: $1,000 → $800
Current: $0.73
Upside: +109,085.21%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $20.70
Upside: +122.22%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $29.52
Upside: +225.20%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.83
Upside: +4,245.20%
Dec 23, 2021
Initiates: Buy
Price Target: $12
Current: $0.37
Upside: +3,117.16%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $4.62
Upside: +571.00%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $614.76
Upside: -94.14%